Virginie Nerich

Prof. Dr. Virginie Nerich

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2011 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
VNVirginie Nerich
Virginie Nerich
PJP. Jantchou
P. Jantchou
MBM.-C. Boutron-Ruault
M.-C. Boutron-Ruault
EME. Monnet
E. Monnet
AWA. Weill
A. Weill
FCF. Carbonnel
F. Carbonnel
Aliment Pharmacol Ther 2011; 33: 940–945 Summary Background Low sunshine exposure might contribute to the pathogenesis of inflammatory bowel disease (IBD). Aim To assess the geographic distribution of IBD incidence in relation to sunshine exposure in France to test the hypothesis that higher sun exposure is associated with lower IBD risk. Methods Using the national health insurance database, incidence rates of Crohn’s disease (CD) and ulcerative colitis (UC) were estimated for each of the 94 French administrative areas (‘départements’), between 2000 and 2002. The surface UV radiation intensity was obtained by combining modelling and satellite data from Meteosat, the European meteorological satellite. Relationships between incidence rates and sun exposure were tested for significance by using a Poisson regression. We mapped smoothed relative risks (sRR) for CD and UC, using a Bayesian approach and adjusting for sun exposure, to search for geographical variations. Results Areas with a smoothed RR of CD incidence significantly above 1 corresponded to areas with low sunshine exposure, whereas those with high or medium sunlight exposure had smoothed RRs either lower than 1 or not significantly different from 1. There was no association between sun exposure and UC incidence. Conclusions This geographic study suggests that low sunlight exposure is associated with an increased incidence of Crohn's disease. Further studies are needed to determine if this association is causal.

1 February 2014 in OncoTargets and Therapy
Verified
Journal Article
Open access
VNVirginie Nerich
Virginie Nerich
MHMarion Hugues
Marion Hugues
TNThierry Nai
Thierry Nai
USUlrich Stein
Ulrich Stein
THThierry Nguyen Tan Hon
Thierry Nguyen Tan Hon
ATAntoine Thiery-Vuillemin
Antoine Thiery-Vuillemin
Introduction: The aim of this retrospective clinical study was to assess, in the context of the recent evolution of systemic therapies, the potential effect of targeted therapies on overall survival (OS) of patients with metastatic clear-cell renal cell carcinoma (mccRCC) in daily practice. Patients and methods: All consecutive patients with histologically confirmed mccRCC who received systemic therapy between January 2000 and December 2010 in two oncology treatment centers in our Franche-Comté region in eastern France were included in the analysis. The primary end point was OS. The analysis of prognostic factors was performed using a two-step approach: univariate then multivariate analysis with a stepwise Cox proportional hazards regression model. Results: For the entire cohort of 111 patients, the median OS was 17 months (95% confidence interval [CI]; 13–22 months) and the two-year OS was 39%. Three prognostic factors were independent predictors of long survival: prior nephrectomy (hazard ratio =0.38 [0.22–0.64], P<0.0001); systemic therapy by targeted therapy (hazard ratio =0.50 [0.31–0.80], P=0.005); and lack of liver metastasis (hazard ratio =0.43 [0.22–0.82], P=0.002). Median OS was 21 months [14–29 months] for patients who received at least one targeted therapy compared with 12 months [7–15 months] for patients who were treated only by immunotherapy agents (P=0.003). Conclusion: Our results suggest that targeted therapies are associated with improved OS in comparison with cytokines, which is in line with other publications.

16 April 2019 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ACAnne-Laure Clairet
Anne-Laure Clairet
MBMarie Boiteux-Jurain
Marie Boiteux-Jurain
ECElsa Curtit
Elsa Curtit
MJMarie Jeannin
Marie Jeannin
BGBlandine Gérard
Blandine Gérard
SLSamuel Limat
Samuel Limat

16 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
RHRana El Haidari
Rana El Haidari
Linda Abou-AbbasLinda Abou-Abbas
Linda Abou-Abbas
VNVirginie Nerich
Virginie Nerich
AAAmélie Anota
Amélie Anota
Objectives: The aim of the present systematic review was to identify the factors that potentially influence health-related quality of life (HRQoL) in women with breast cancer (BC) in the Middle East. Methods: A systematic search of the PubMed, Ovid Medline, Cochrane, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Ebscohost databases was conducted to identify all relevant articles published in peer-reviewed journals up to April 2018. The keywords were “Health related quality of life”, “Breast Cancer”, and “Middle East countries”. The Newcastle–Ottawa (NOS) scale was used to evaluate the methodological quality of the included studies. Due to the methodological heterogeneity of the identified studies, no statistical pooling of the individual effect estimates was carried out; instead, the results were summarized descriptively. Results: A total of 5668 articles were screened and 33 studies were retained. The vast majority of these studies were cross-sectional and only two were longitudinal prospective studies. Concerning the methodological quality, only 39% were of high quality. Our comprehensive literature review identified several modifiable and non-modifiable risk factors associated with HRQoL, including sociodemographic, clinical, and treatment-related factors as well as behavioral and psychosocial factors. Conclusion: This study has many implications for clinical practice and may provide a framework for establishing policy interventions to improve HRQoL among women with BC. Healthcare systems in the Middle East are encouraged to develop interventional programs targeting modifiable factors, particularly socio-demographic, behavioral, and psychosocial factors.

15 June 2020 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
VNVirginie Nerich
Virginie Nerich
EGEva Maria Gamper
Eva Maria Gamper
RNRichard Norman
Richard Norman
MKMadeleine King
Madeleine King
BHBernhard Holzner
Bernhard Holzner
GKGeorg Kemmler
Georg Kemmler

1 May 2022 in Therapies
Verified
Journal Article
Closed access
MTMarion Tissot
Marion Tissot
MVMarie-Blanche Valnet-Rabier
Marie-Blanche Valnet-Rabier
TSThomas Stalder
Thomas Stalder
SLSamuel Limat
Samuel Limat
SDSiamak Davani
Siamak Davani
VNVirginie Nerich
Virginie Nerich